


**Product Name** : Rocilinostat  
**Cat. No.** : PC-73193  
**CAS No.** : 1316214-52-4  
**Molecular Formula** : C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 433.5  
**Target** : HDAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

Rocilinostat (ACY-1215) is a potent and selective HDAC6 inhibitor with IC<sub>50</sub> of 5 nM.

Rocilinostat (ACY-1215) displays 10-12 fold less active against HDAC1, HDAC2, and HDAC3 (class I HDACs), minimal activity (IC<sub>50</sub> > 1 uM) against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2, and has slight activity against HDAC8 (IC<sub>50</sub>=0.1 uM). ACY-1215 induces dose-dependent cytotoxicity in MM cells (IC<sub>50</sub>=2-8 uM), induces synergistic anti-MM activity in combination with bortezomib.

ACY-1215 in combination with bortezomib induces significant anti-MM activity in vivo.

## References

Santo L, et al. Blood. 2012 Mar 15;119(11):2579-89.

Amengual JE, et al. Clin Cancer Res. 2015 Oct 15;21(20):4663-75.

Mishima Y, et al. Br J Haematol. 2015 May;169(3):423-34.

Dasmahapatra G, et al. Mol Cancer Ther. 2014 Dec;13(12):2886-97.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com